Skip to main content
IMUGENE LIMITED logo

IMUGENE LIMITED — Investor Relations & Filings

Ticker · IMU ISIN · AU000000IMU9 LEI · 984500A5C9KF08EAF248 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,444 across all filing types
Latest filing 2004-06-24 Share Issue/Capital Cha…
Country AU Australia
Listing ASX IMU

About IMUGENE LIMITED

https://imugene.com

Imugene Limited is a clinical-stage immuno-oncology company focused on developing immunotherapies to activate the immune system against various cancers. The company’s pipeline features multiple platform technologies, including B-cell activating immunotherapies, oncolytic viruses, and CAR-T cell enhancement therapies. Key clinical candidates include HER-Vaxx, targeting HER2-positive gastric cancer, and PD1-Vaxx, a checkpoint inhibitor immunotherapy. Imugene is also advancing the CF33 oncolytic virus platform, which includes VAXINIA and CHECKvacc, alongside the onCARlytics program. The onCARlytics platform is designed to enable CAR-T cells to target solid tumors by inducing the expression of CD19 on cancer cell surfaces. These programs aim to address unmet needs in oncology by providing targeted, potent, and potentially less toxic alternatives to conventional treatments.

Recent filings

Filing Released Lang Actions
Appendix 3B - Conversion of CPS 10 pages ?Kb
Share Issue/Capital Change Classification · 95% confidence The document is an ASX announcement dated June 25, 2004, regarding the automatic conversion of Convertible Preference Shares into ordinary shares. It includes detailed information about the number of shares converted, the terms of the securities, and references to Appendix 3B, which is a standard form for new issue announcements and applications for quotation of additional securities on the ASX. The document is focused on capital structure changes, specifically the conversion of preference shares into ordinary shares, and the issuance of new shares as a result. There is no financial performance data, management discussion, or audit information. The document is not a report but an announcement of a capital change event. Therefore, it fits best under the category of Share Issue/Capital Change (SHA). The document length is substantial (15,000 characters), but it is clearly an announcement of a capital change event, not a full financial report or other category.
2004-06-24 English
Development Plans -E. coli Treatment for Pigs 3 pages ?Kb
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated June 22, 2004, detailing Imugene Limited's commercial development plans for a new product treating E. coli in pigs. It discusses product development, animal trials, manufacturing, regulatory process, distribution, and market potential. There are no financial statements, earnings data, or detailed financial analysis. The document is a corporate announcement about product development and commercialization plans rather than a financial report or regulatory filing. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Capital Update. It is not a management or board change announcement, nor a voting result or legal proceeding. The content is primarily an update on product development and commercialization plans, which aligns best with a general Regulatory Filing (RNS) as a miscellaneous corporate announcement that does not fit other specific categories. The document length is about 5140 characters, sufficient for a substantive announcement but not a full report. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2004-06-21 English
Securities Ceasing Escrow 1 page ?Kb
Regulatory Filings Classification · 90% confidence The document is an ASX announcement dated June 9, 2004, regarding the cessation of escrow on certain shares. It is a brief announcement about securities ceasing escrow, which relates to changes in share restrictions but does not involve detailed financial data, management changes, or voting results. It is not a full report, earnings release, or regulatory filing with substantive financial content. The content fits best under a general regulatory announcement category related to securities status updates. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2004-06-08 English
Trading Halt 2 pages ?Kb
Regulatory Filings Classification · 95% confidence The document is a market release dated 20 May 2004 from Imugene Limited announcing a trading halt requested by the company pending a forthcoming announcement. It is a short notice about the suspension of trading and does not contain financial data, report content, or detailed disclosures. It is not a financial report, earnings release, or management discussion. It is a regulatory announcement related to trading status. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2004-05-19 English
Licenses New Technology for Pig Gastrointestinal Diseases 5 pages ?Kb
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated May 20, 2004, regarding Imugene licensing a new technology for pig gastrointestinal diseases. It details the technology, patents, animal trials, and company background. There are no financial statements, regulatory certifications, or voting results. The content is a corporate announcement about a licensing deal and new product development, not a financial report, earnings release, or management discussion. It is not a report publication announcement since it contains substantive information rather than just a notice. Therefore, the document fits best as a Capital/Financing Update (CAP) because it announces a licensing agreement and related commercial terms (milestone payments and royalties).
2004-05-19 English
Commitments Test Entity - Third Quarter Report 9 pages ?Kb
Interim / Quarterly Report Classification · 95% confidence The document is an ASX announcement titled 'Market Update' dated April 30, 2004, from Imugene Limited. It discusses progress on vaccine development, regulatory processes, patents, new projects, and market strategies. The document also includes an Appendix 4C, which is a quarterly report for entities admitted on the basis of commitments, containing detailed cash flow statements for the quarter ended March 31, 2004. Appendix 4C is a recognized quarterly report format under ASX rules. The presence of substantive financial data and analysis in the cash flow statements confirms this is a quarterly report rather than a mere announcement or summary. Therefore, the document fits the definition of an Interim / Quarterly Report (IR).
2004-04-29 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.